Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

linsitinib

Phase 3Small molecule

SSling Therapeutics, Inc.

1

Indications

9

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid Eye Disease, TEDRecruiting

Thyroid Eye Disease, TEDPhase 3

Recruiting

Timeline

Expected Milestones

Q2 2030

Phase 3Recruiting

Thyroid Eye Disease, TED

NCT07753603

Clinical

Trials by Indication[1]

Thyroid Eye Disease2 trials

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Recruiting·SSling Therapeutics, Inc.·Phase 2/3·NCT06112340·75 enrolled

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Completed·SSling Therapeutics, Inc.·Preclinical·NCT05276063·90 enrolled

Ewing sarcoma1 trial

Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

Completed·UUniversity of Oxford·Phase 2·NCT02546544·16 enrolled

Gastrointestinal Stromal Tumor1 trial

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01560260·20 enrolled

Small Cell Lung Cancer1 trial

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01533181·44 enrolled

Metastatic Prostate Cancer1 trial

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01533246·17 enrolled

3 more indications

Cutaneous Squamous Cell Carcinoma1 trial

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Withdrawn·OOHSU Knight Cancer Institute·Phase 1/2·NCT01465815

Trial1 trial

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Completed· Astellas logo

Astellas·Phase 2·NCT02057380·13 enrolled

Thyroid Eye Disease, TED1 trial

A Phase 3, Randomized, Double-mask, Placebo-controlled Study With Open-label Extension to Evaluate the Efficacy and Safety of Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

Recruiting·SSling Therapeutics, Inc.·Phase 3·NCT07753603·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for linsitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — linsitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for linsitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sling Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSling Therapeutics, Inc.

Related News